Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBT076 +/- Balstilimab in Recurrent/Metastatic Adenoid Cystic Carcinoma
NCT05930951Phase 1Terminated
- Sponsor
- GORTEC
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of OBT076 in adenoid cystic carcinoma (ACC) (2 arms), sponsored by GORTEC. Primary endpoint: Objective Response Rate at 1 year. Started Nov 2023; status: terminated.
02
Drugs
OBT076
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT05930951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930951.